Compounding involves customizing medications to suit individual patient needs (such as creating a liquid form of a drug that’s originally available only as a pill or injectable). Additionally, compounding pharmacies can create medications that can be in short supply (such as GLP-1 medications).

These compounded medications are prepared by state-licensed pharmacies that adhere to FDA and state regulations, ensuring quality standards. Compounded medications are not approved nor evaluated for safety or effectiveness by the FDA.

Oak has partnered with the foremost compounding pharmacies to provide compounded semaglutide and tirzepatide, containing the same active ingredient as Ozempic®, Wegovy®, Mounjaro®, and Zepound®. Oak does NOT use semaglutide salts, which differ from the active ingredients mentioned above.

Oak works with state-licensed 503B compounding pharmacies to produce compounded medications (not 503A). A licensed compounding pharmacy must comply with both federal and state laws, which include administrative requirements and quality standards.

503B pharmacies that are overseen by the Food and Drug Administration (FDA); quality standards for 503B facilities are much more stringent and include:

• Reviewing and confirming quality for all base lots, which are received from FDA-registered manufacturers;
• Storing the verified pharmaceutical components frozen and sealed until use;
• Compounding with the active components under aseptic processes to produce specific lots (vials)
• + more

Compounded medications are available through Oak in most states aside from California (our brand name GLP-1s are still available in most states). We will have a compounding option in California soon!